金陵药业：分公司收到碳酸司维拉姆干混悬剂受理通知书

Core Viewpoint - Jinling Pharmaceutical (000919) has received a notice of acceptance from the National Medical Products Administration for its drug, Carbonate Sevelamer Dry Suspension, aimed at treating hyperphosphatemia in adult patients with chronic kidney disease undergoing dialysis [1] Group 1 - The acceptance number for the drug is CYHS2501638 [1] - The drug is primarily indicated for controlling hyperphosphatemia in adult patients with chronic kidney disease who are receiving dialysis [1] - Following the acceptance of the registration application, the drug will proceed to the review and approval stage at the National Medical Products Administration's Drug Evaluation Center, with completion time and approval results being uncertain [1]